Steven B. Maron

Mar 21, 2024 | jnm.snmjournals.org | Samuel Cytryn |Neeta Pandit-Taskar |Melissa Lumish |Steven B. Maron

MATERIALS AND METHODSThis was a single-institution prospective pilot open-label microdose PET evaluating the PD-L1–targeting radiotracer 18F-BMS-986229 with PET imaging in 10 patients with GEC between February 3, 2020 and February 2, 2022. Ten (100%) patients had adenocarcinoma, 7 (70%) had metastatic disease, and 3 (30%) had received prior treatment at the time of PD-L1 PET imaging, including 2 with PD-1 inhibitors (Table 1). The median PD-L1 CPS was 10 (interquartile range, 5–20).

Apr 28, 2023 | jnm.snmjournals.org | Melissa Lumish |Steven B. Maron |Viktoriya Paroder |Joanne F. Chou

Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.